Leerink Swann upped their price target on shares of Medtronic (NYSE: MDT) from $48.00 to $52.00 in a research note issued on Wednesday, Analyst Ratings.Net reports. The firm currently has a “market perform” rating on the stock.

MDT has been the subject of a number of other recent research reports. Analysts at JPMorgan Chase reiterated a “neutral” rating on shares of Medtronic in a research note to investors on Wednesday. They now have a $49.00 price target on the stock. Separately, analysts at Sanford C. Bernstein reiterated an “outperform” rating on shares of Medtronic in a research note to investors on Tuesday. They now have a $55.00 price target on the stock. Finally, analysts at Piper Jaffray reiterated an “overweight” rating on shares of Medtronic in a research note to investors on Monday. They now have a $50.00 price target on the stock.

Twelve research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $50.31.

Shares of Medtronic (NYSE: MDT) traded up 0.18% during mid-day trading on Wednesday, hitting $50.01. Medtronic has a 52 week low of $35.67 and a 52 week high of $49.93. The stock’s 50-day moving average is currently $47.1. The company has a market cap of $50.700 billion and a P/E ratio of 14.76.

Medtronic (NYSE: MDT) last issued its quarterly earnings data on Tuesday, February 19th. The company reported $0.93 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.91 by $0.02. The company had revenue of $4.03 billion for the quarter, compared to the consensus estimate of $4.03 billion. During the same quarter in the prior year, the company posted $0.88 earnings per share. The company’s quarterly revenue was up 2.8% on a year-over-year basis. Medtronic has set its FY13 guidance at $3.66-3.70 EPS. Analysts expect that Medtronic will post $3.69 EPS for the current fiscal year.

Medtronic, Inc. (NYSE: MDT) is engaged in medical technology – alleviating pain, restoring health, and extending life for millions of people worldwide.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.